This is a working overview of Melanotan II, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-07-25 and is reviewed periodically as new material appears.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Vitarine Pharmaceuticals of New York, which sought approval of a generic version of the drug Dyazide, a medication for high blood pressure, submitted Dyazide, rather than its generic version, for the FDA tests. In April 1989, the FDA investigated 11 manufacturers for irregularities; and later brought that number up to 13. Dozens of drugs were eventually suspended or recalled by manufacturers. In the early 1990s, the U.S. Securities and Exchange Commission filed securities fraud charges against the Bolar Pharmaceutical Company, a major generic manufacturer based in Long Island, New York.
However, all annealing based assembly methods require the primers to be mixed together in one tube. In this case, shorter overlaps do not always allow precise and specific annealing of complementary primers, resulting in the inhibition of full length product formation. Manual design of oligonucleotides is a laborious procedure and does not guarantee the successful synthesis of the desired gene. For optimal performance of almost all annealing based methods, the melting temperatures of the overlapping regions are supposed to be similar for all oligonucleotides. The necessary primer optimisation should be performed using specialized oligonucleotide design programs. Several solutions for automated primer design for gene synthesis have been presented so far.
SR-15099, also known as SR 2.0, is an atypical opioid and close analogue of SR-17018 and brorphine. It is the analogue of SR-17018 in which the chlorine atom on the benzyl ring has been replaced with a bromine atom. The drug is a non-competitive partial biased agonist of the μ-opioid receptor (MOR) similarly to SR-17018. It has similar effects in animals as SR-17018, such as having robust analgesic effects but producing minimal respiratory depression or hyperlocomotion. SR-15099 was first described in the scientific literature by Laura M. Bohn and colleagues by 2017.
Sources: en.wikipedia.org
=== Organic chemistry research === Oleum is a harsh reagent, and is highly corrosive. One important use of oleum as a reagent is the secondary nitration of nitrobenzene. The first nitration can occur with nitric acid in sulfuric acid, but this deactivates the ring towards further electrophilic substitution. A stronger reagent, oleum, is needed to introduce the second nitro group onto the aromatic ring.
Defending against a full Russian or Chinese attack would require hundreds of thousands of satellites," according to MIT physicists Lisbeth Gronlund and David Wright. The cost of launching satellites is expected to decrease when the heavy-lift SpaceX Starship launch vehicle enters service. Still, the extreme expense of creating such a constellation—and replacing satellites as their orbits decay—has led the U.S. military to also pursue space-based midcourse options that would require fewer satellites. But these would be more expensive and no better than ground-based interceptors at telling decoys from warheads. Space-based interceptors would be guided by the nascent Hypersonic and Ballistic Tracking Space Sensor system, one of the tracking elements of the Space Development Agency's (SDA) seven-layer Proliferated Warfighter Space Architecture (PWSA). The Golden Dome would also be aimed at detecting and countering strikes delivered from a fractional orbital bombardment system (FOBS). Pentagon leaders have said the system could be used to put offensive weapons in space, giving a global strike capability that would create offensive overmatch. Defense Secretary Pete Hegseth has said the U.S. "will be able to strike anywhere, anytime". Satellites might carry the bunker-busting Common-Hypersonic Glide Body (C-HGB), which can reportedly fly 1,000 miles to strike within 14 inches of its target. The missile was designed to fit the HIMARS ground launcher, so several can be compactly racked in a satellite payload bays.
The continuous and discrete spectra of physical systems can be modeled in functional analysis as different parts in the decomposition of the spectrum of a linear operator acting on a function space, such as the Hamiltonian operator. The classical example of a discrete spectrum (for which the term was first used) is the characteristic set of discrete spectral lines seen in the emission spectrum and absorption spectrum of isolated atoms of a chemical element, which only absorb and emit light at particular wavelengths. The technique of spectroscopy is based on this phenomenon. Discrete spectra are seen in many other phenomena, such as vibrating strings, microwaves in a metal cavity, sound waves in a pulsating star, and resonances in high-energy particle physics. The general phenomenon of discrete spectra in physical systems can be mathematically modeled with tools of functional analysis, specifically by the decomposition of the spectrum of a linear operator acting on a functional space.
Sources: en.wikipedia.org
Conduction velocity The speed at which an action potential travels along a nerve fiber. It is influenced by factors such as axon diameter and myelination. Consciousness A state of awareness of self and the environment. In neuroscience, it involves the coordinated activity of multiple brain regions, particularly the thalamocortical system. Corpus callosum The largest white matter structure in the brain, consisting of a thick band of axons that connects the left and right cerebral hemispheres. Cortical column A vertically organized group of neurons in the cerebral cortex that processes the same type of information, such as orientation or location in space. It is a basic functional unit of the cortex. Cortical plasticity The ability of the cerebral cortex to adapt and reorganize in response to experience, learning, or injury. Corticospinal tract A major descending pathway from the motor cortex to the spinal cord that mediates voluntary motor control, especially fine movements of the limbs. Creutzfeldt–Jakob disease (CJD) A rare and fatal neurodegenerative disorder caused by misfolded prion proteins. It leads to rapid cognitive decline, motor dysfunction, and ultimately death. Critical period A developmental window during which the nervous system is particularly sensitive to certain environmental stimuli, crucial for proper development of functions such as vision and language. Cross modal plasticity The ability of one sensory modality to reorganize and compensate in another’s absence (e.g., visual cortex being recruited for touch in individuals who are blind).
The federal constitution stipulates that the structure of each Federated State's government must "conform to the principles of republican, democratic, and social government, based on the rule of law" (Article 28). Most of the states are governed by a cabinet led by a Ministerpräsident (minister-president), together with a unicameral legislative body known as the Landtag (State Diet). The states are parliamentary republics and the relationship between their legislative and executive branches mirrors that of the federal system: the legislatures are popularly elected for four or five years (depending on the state), and the minister-president is then chosen by a majority vote among the Landtag's members. The minister-president is typically the head of the biggest party of a coalition. The minister-president appoints a cabinet to run the state's agencies and to carry out the executive duties of the state's government. Like in other parliamentary systems, the legislature can dismiss or replace the minister-president after a successful no-confidence vote. The governments in Berlin, Bremen and Hamburg are referred to as "senates". In the free states of Bavaria and Saxony, the government is referred to as "state government" (Staatsregierung); and in the other states, the government is referred to as "Land government" (Landesregierung). Before 1 January 2000, Bavaria had a bicameral parliament, with a popularly elected Landtag, and a Senate made up of representatives of the state's major social and economic groups. The Senate was abolished following a referendum in 1998.
Specific vitamin A supplementation is particularly important for preventing further damage to the liver and skin. Ready-to-use therapeutic foods (RUTFs) and F-75 and F-100 milks were created to provide appropriate nutrition and caloric intake to those experiencing malnutrition. F-75 milk would be ideal when trying to reintroduce food into a malnourished person, and F-100 milk would be used to aid in weight gain. While RUTFs and F-100 milk were made to have the same nutritional value, RUTFs are beneficial as they are dehydrated and do not require much preparation. It is also important to note that infections are common in children with severe malnutrition and can further complicate treatment. Routine antibiotics, even in the absence of clinical infection, are generally given as a prophylactic measure, especially in regions with a high risk of infectious diseases. However, due to concerns about antibiotic resistance, there is debate over their routine use.
Of the two who did not show breast development, one had only been on bicalutamide for 2 months and the other progressed to Tanner stage 3 at the second follow-up at 12.5 months after starting bicalutamide. Testosterone levels (n=5) were 524 to 823 ng/dL and estradiol levels (n=6) were <20 to 61 pg/mL in the patients. Liver function tests were performed and were all normal. Although GnRH modulators are the first-line treatment to prevent puberty in transgender adolescents, they are very expensive and are often denied by medical insurance. According to the researchers, bicalutamide represents a potential alternative to GnRH modulators as a puberty blocker in transgender girls. Studies assessing bicalutamide as an antiandrogen in transgender women are very limited. In any case, besides the study of bicalutamide as a puberty blocker in transgender girls, it has been found to be effective as an antiandrogen in women with hirsutism due to hyperandrogenism and in boys with gonadotropin-independent precocious puberty, and demasculinization and feminization are well-documented effects of bicalutamide in men treated with it for prostate cancer. In addition, nilutamide, a closely related antiandrogen with the same mechanism of action as bicalutamide, has been evaluated in transgender women in at least five small published clinical studies by the same group of researchers. It was given at a relatively high dosage of 300 mg/day, the same dosage at which it has been used as a monotherapy in the treatment of prostate cancer.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.